UPDATE: Ariad Pharma (ARIA) Iclusig Launch Not Without Risks; Minority of Physicians View Warnings as Prohibitive
Tweet Send to a FriendGet Alerts ARIA Hot Sheet
Price: $19.58 +0.72%
Rating Summary:
15 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 13
Rating Summary:
15 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 13
Trade ARIA Now!
(Updated - January 3, 2013 11:18 AM EST)
A US survey on ARIAD Pharmaceuticals' (NASDAQ: ARIA) Iclusig suggests some risk to launch, said Oppenheimer. Following the drug's approval by the FDA, which included a box warning arterial thrombosis and liver toxicity, analyst conducted a physician survey.
"The results do not diminish our confidence in Iclusig's significant long-term market opportunity. However, the survey revealed some increased physician caution around Iclusig's side effects and initial adoption,” said analyst David Ferreiro, Ph.D.
"The large majority of surveyed physicians maintained a strong view of Iclusig's profile, despite Iclusig's boxed warning. However, there appears to have emerged a 15% minority of physicians who find Iclusig's arterial thrombosis and liver toxicity to be prohibitive,” said Ferreiro.
Oppenheimer has a Perform rating on ARIAD Pharmaceuticals with a price target of $23.00.
For an analyst ratings summary and ratings history on ARIAD Pharmaceuticals (NASDAQ: ARIA) click here. For more ratings news on ARIAD Pharmaceuticals click here.
Shares of ARIAD Pharmaceuticals closed at $20.09 yesterday, with a 52 week range of $12.26-$25.40.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
A US survey on ARIAD Pharmaceuticals' (NASDAQ: ARIA) Iclusig suggests some risk to launch, said Oppenheimer. Following the drug's approval by the FDA, which included a box warning arterial thrombosis and liver toxicity, analyst conducted a physician survey.
"The results do not diminish our confidence in Iclusig's significant long-term market opportunity. However, the survey revealed some increased physician caution around Iclusig's side effects and initial adoption,” said analyst David Ferreiro, Ph.D.
"The large majority of surveyed physicians maintained a strong view of Iclusig's profile, despite Iclusig's boxed warning. However, there appears to have emerged a 15% minority of physicians who find Iclusig's arterial thrombosis and liver toxicity to be prohibitive,” said Ferreiro.
Oppenheimer has a Perform rating on ARIAD Pharmaceuticals with a price target of $23.00.
For an analyst ratings summary and ratings history on ARIAD Pharmaceuticals (NASDAQ: ARIA) click here. For more ratings news on ARIAD Pharmaceuticals click here.
Shares of ARIAD Pharmaceuticals closed at $20.09 yesterday, with a 52 week range of $12.26-$25.40.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- Janney Capital Boosts PT on Gap (GPS) Post Q1
- Needham & Company Lifts Numbers on Marvell (MRVL) on Solid Results
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
